drugset / Trial / NCT02413827
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining a) varlilumab and ipilimumab and b) varlilumab, ipilimumab, CDX-1401 and poly-ICLC. The study will enroll patients with unresectable Stage III or Stage IV melanoma.
Timeline
- Start
- 2015-04
- Primary completion
- 2016-11-02
- Completion
- 2016-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hiltonol | Other / unclassified | 2 mg | — |
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | RASDEGAFUSP ALFA | Vaccine | 1 mg | — |
| Subject | Varlilumab | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | Varlilumab | Monoclonal antibody | 3 mg/kg | — |